Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Dodge & Cox

Dodge & Cox reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,180,666 shares of the company's stock after selling 134,884 shares during the quarter. Dodge & Cox owned approximately 16.83% of Elanco Animal Health worth $1,007,318,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC grew its stake in Elanco Animal Health by 28.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after buying an additional 2,264 shares during the last quarter. DDD Partners LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter valued at about $5,974,000. Geode Capital Management LLC raised its position in shares of Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock valued at $115,623,000 after purchasing an additional 65,303 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock worth $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock worth $5,349,000 after purchasing an additional 45,795 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ELAN shares. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. UBS Group lowered their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus cut their price objective on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Morgan Stanley decreased their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, Barclays cut their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Elanco Animal Health has a consensus rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded up $0.34 during midday trading on Friday, hitting $8.44. 5,406,589 shares of the company were exchanged, compared to its average volume of 4,915,626. The business has a fifty day simple moving average of $10.26 and a two-hundred day simple moving average of $11.83. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market capitalization of $4.19 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business earned $0.08 EPS. Elanco Animal Health's revenue for the quarter was down 1.4% compared to the same quarter last year. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.